VATS vs SABR for Stage I operable NSCLC

Just saw this in Lancet Oncology: Link Caveats are that it is a single, arm prospective trial and the comparison to surgical arm was based on case-matching, not randomization. But still both arms show overall survival of 91% at three years. Finally a bit of good news in RO.
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums